NASDAQ: MGXMetagenomi Therapeutics Inc Stock
$1.20+0.02 (+1.69%)
Updated Jun 18, 2026
MGX Price
$1.20
Fair Value Price
N/A
Market Cap
$45.18M
52 Week Low
$1.13
52 Week High
$3.95
P/E
-0.52x
P/B
0.33x
P/S
2.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$22.33M
Earnings
-$85.89M
Gross Margin
100%
Operating Margin
-385.27%
Profit Margin
-384.6%
Debt to Equity
0.43
Operating Cash Flow
-$87M
Beta
1.09
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MGX Overview
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MGX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MGX
Ranked#395 of 465
Ranked#395 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important MGX news, forecast changes, insider trades & much more!
MGX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MGX is good value based on its book value relative to its share price (0.33x), compared to the US Biotechnology industry average (4.95x)
P/B vs Industry Valuation
MGX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MGX due diligence checks available for Premium users.
Valuation
MGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.52x
Industry
15.77x
Market
9.47x
MGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.33x
Industry
4.95x
MGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGX's financial health
Profit margin
Revenue
$1.2M
Net Income
-$23.1M
Profit Margin
-1,847.7%
MGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MGX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$197.0M
Liabilities
$59.2M
Debt to equity
0.43
MGX's short-term assets ($144.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGX's short-term assets ($144.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.2M
Investing
$4.0M
Financing
-$27.0k
MGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGX vs Biotech Stocks
Metagenomi Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.